412 results on '"Lawrance, Ian C."'
Search Results
2. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
3. Level of UV Exposure, Skin Type, and Age Are More Important than Thiopurine Use for Keratinocyte Carcinoma Development in IBD Patients
4. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
5. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis
6. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes
7. Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer
8. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
9. Crohn's disease management after intestinal resection: a randomised trial
10. An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis
11. Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD
12. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study
13. Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease
14. Cellular and Molecular Mediators of Intestinal Fibrosis
15. High Dose Vitamin D supplementation alters faecal microbiome and predisposes mice to more severe colitis
16. Crohn's disease and smoking: Is it ever too late to quit?
17. Prostaglandin E2 and Polyenylphosphatidylcholine Protect Against Intestinal Fibrosis and Regulate Myofibroblast Function
18. Indications and selection of MR enterography vs. MR enteroclysis with emphasis on patients who need small bowel MRI and general anaesthesia: results of a survey
19. Inter-observer agreement for Crohn's disease sub-phenotypes using the Montreal Classification: How good are we? A multi-centre Australasian study
20. Mo1833 DOSE ESCALATED USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
21. Tu1891 THE REAL-WORLD USE OF FIVE-AMINOSALICYLATE (5ASA) TREATMENT FOR ULCERATIVE COLITIS IN AUSTRALIA AND NEW ZEALAND: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM
22. Mo1835 DOSE ESCALATED INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
23. Mo1834 DOSE ESCALATED VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
24. Su1874 THE BURDEN OF MENTAL HEALTH DISEASE IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
25. Su1841 VARIATION IN OUTCOMES IN INFLAMMATORY BOWEL DISEASE AT TEN AUSTRALASIAN CENTRES - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
26. An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis.
27. Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
28. An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis
29. Emu Oil Attenuates Disease Severity and Results in Fewer Large Colonic Tumors in a Mouse Model of Colitis-Associated Colorectal Cancer
30. Fine-mapping inflammatory bowel disease loci to single-variant resolution
31. Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease:Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes
32. Knowledge, Quality of Life, and Use of Complementary and Alternative Medicine and Therapies in Inflammatory Bowel Disease: A Comparison of Chinese and Caucasian Patients
33. Natalizumab induction and maintenance therapy for Crohn's disease
34. NAFLD, the changing face of IBD
35. Oral tacrolimus in the treatment of medically refractory IBD patients
36. Clinical risk stratification accurately predicts development of endoscopic recurrence after Crohnʼs disease surgery: early results from the prospective POCER study
37. Adalimumab prevents post-operative Crohnʼs disease recurrence, and is superior to thiopurines: early results from the POCER study
38. SPARC enhances intestinal inflammation in dextran sodium sulphate-induced murine colitis
39. Prostaglandin E2 regulates intestinal inflammation and modifies in vivo and in vitro extracellular matrix regulation
40. Dysregulation of innate immune signalling in ulcerative colitis
41. Phosphatidylcholine regulates intestinal inflammation and modifies in vivo and in vitro extracellular matrix regulation
42. SPARC modifies colonic tissue healing and inflammation by regulating collagen and MMP expression
43. Tumour microenvironment differs between murine sporadic and inflammation-associated colorectal tumorigenesis
44. Liver iron homeostasis is altered by colonic inflammation and dietary iron
45. Microbiota and management of inflammatory bowel disease
46. Orally administered emu oil attenuates disease in a mouse model of Crohn’s-like colitis
47. The role of a plant-based diet in the pathogenesis, etiology and management of the inflammatory bowel diseases
48. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: An Australian and New Zealand experience
49. Ecabet sodium: A potential new agent in the management of distal colitis
50. Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.